ESR1 and breast carcinoma: Moreover, KGF administration has been shown to increase cell motility in estrogen receptor (ER)-positive breast tumor cells [15], [16], to be potentially involved in breast cancer progression and metastasis [17] and to enhance the invasive potential of gastric carcinoma derived cell lines overexpressing KGFR [18].